Overview
VNDA market data
Price History
VNDA price chart · 1M
- O
- 5.35
- H
- 5.49
- L
- 5.35
- C
- 5.43
- Vol
- 42,050.00
- Source
- US equities market feed
- Observed
- Aug 25, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $5.35
- Previous Close
- $5.32
- Day High
- $5.49
- Day Low
- $5.35
- 52 Week High
- $9.94
- 52 Week Low
- $4.48
- 7 Day Return
- -0.37%
- 30 Day Return
- +3.82%
- 90 Day Return
- -16.01%
- 1 Year Return
- -31.35%
- Daily Notional Volume
- $228.3K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.74 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.66 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -110.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $4.27 – $9.94 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $304.3M · P/B 1.59 · P/S 1.40.
Company News
Vanda Pharmaceuticals Receives EMA Orphan Designation For Imsidolimab For The Treatment Of Generalized Pustular PsoriasisBenzinga · Aug 24, 2026, 1:28 PM
B. Riley Securities Reiterates Buy on Vanda Pharmaceuticals, Lowers Price Target to $12Benzinga · Aug 10, 2026, 5:17 PM
HC Wainwright & Co. Maintains Buy on Vanda Pharmaceuticals, Lowers Price Target to $20Benzinga · Aug 10, 2026, 10:23 AM
Vanda Pharma Q2 EPS $(1.04) Misses $(0.59) Estimate, Sales $50.529M Miss $61.925M EstimateBenzinga · Aug 5, 2026, 8:06 PM
Vanda Pharmaceuticals Affirms FY2026 Sales Guidance of $240.000M-$290.000M vs $262.154M EstBenzinga · Aug 5, 2026, 8:05 PM
Vanda Pharmaceuticals Announces European Medicines Agency Adopts Positive Opinion For Orphan Drug Designation Of Imsidolimab For Generalized Pustular PsoriasisBenzinga · Jul 16, 2026, 8:32 PM
Vanda Pharma Says FDA Grants Rare Pediatric Disease Designation To VCA-894A For Treatment Of Charcot-Marie-Tooth Disease, Axonal, Type 2SBenzinga · Jul 7, 2026, 8:40 PM